[Proposal for the treatment of cervix dysplasia with immunomodulators].
The study included 60 patients: 43 suffered from slight portio dysplasia (12 had HPV infection also), while 17 had moderate dysplasia (7 had HPV infections also). The treatment was carried out by self-administration in 3 stages: attack (50 mg of thymopentin by s.c. injection every day for two weeks); maintenance (50 mg of thymopentin by s.c. injection every other day for ten weeks); recall 6 months after (50 mg of thymopentin every day for 4 weeks). The drug was well tolerated by all of the patients and the recovery rate in a 9-months follow-up period was significantly higher versus an historical control group.
Serra
G E
GE
Istituto Nazionale per la Ricerca sul Cancro, Genova.
Gustavino
C
C
Serra Cervetti
G G
GG
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016305:Thymopentin / Q000627:therapeutic use*; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D016305:Thymopentin
Proposta di terapia con immunomodulanti nelle displasie cervicali.